Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Core Insights - Hummingbird Bioscience has granted Immunome, Inc. an exclusive worldwide license for monoclonal antibodies targeting a single undisclosed target, highlighting the strategic partnership in developing targeted cancer therapies [1][2][3] Group 1: License Agreement Details - Under the license agreement, Immunome will handle the research, development, manufacturing, and commercialization of products using the licensed antibodies, while Hummingbird will receive an upfront payment along with future milestone payments and royalties [2] - The agreement emphasizes the value of Hummingbird's epitope-focused antibody discovery capabilities, with Immunome recognized for its experience in developing and commercializing novel antibody-drug conjugate (ADC) therapies [3] Group 2: Hummingbird Bioscience Overview - Hummingbird Bioscience is focused on discovering and developing transformative biologics for hard-to-treat diseases, building a pipeline of next-generation ADCs using proprietary antibody discovery and linker/payload platforms [4] - The company has several ADCs in preclinical development and is advancing monoclonal antibodies HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I, with an out-licensed ADC (HMBD-501) set to enter clinical trials in 2025 [4] - Hummingbird employs a Rational Antibody Discovery (RAD) platform that integrates AI-enabled algorithms and immunization strategies to enhance the discovery of high-affinity antibodies, with multiple RAD-derived therapeutics currently in clinical development or partnered [3][4]